FDG positron emission tomography to manage patients with an occult primary carcinoma and metastasis outside the cervical lymph nodes.
D054598:Blue Cross Blue Shield Insurance Plans; D002277:Carcinoma / Q000000981:diagnostic imaging*; D018795:Device Approval; D019788:Fluorodeoxyglucose F18; D006801:Humans; D019458:Insurance Coverage; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D009382:Neoplasms, Unknown Primary / Q000000981:diagnostic imaging; D017063:Outcome Assessment, Health Care; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D013673:Technology Assessment, Biomedical; D014055:Tomography, Emission-Computed / Q000379:methods; D014481:United States; D014486:United States Food and Drug Administration
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18